Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

June 30, 2016


Company: Clonmel Healthcare Ltd.
Legal category: Prescription. GMS. Sport permitted.
Active ingredient: Levocetirizine diHCl 5mg.
Description: White, oval, biconvex film-coated tablets marked L9CZ on one side and 5 on reverse.
Presentation: 30, €5.87.
Indication: Treatment of symptoms of chronic idiopathic urticaria.

Pharmacology: Levocetirizine is a potent and selective antagonist of peripheral H1-receptors. It inhibits the histamine-mediated early phase of the allergic reaction and also reduces the migration of certain inflammatory cells and the release of certain mediators associated with the late allergic response.
Dosage: Adults and children 12 years and over: 5mg once daily. Renal impairment: See SPC. Elderly: As per adults. Children: 6-12 years, 5mg once daily. Under 6 years, not recommended.
Contraindications: Hypersensitivity to levocetirizine, any of the excipients, hydroxyzine or any piperazine derivatives. Severe renal impairment (<10ml/min cc). Special precautions: Caution: Epilepsy, patients at risk of convulsions. Driving/using machines. Contains lactose. Pregnancy, lactation.
Drug interactions: Caution: Alcohol.
Adverse drug reactions: Rhinitis (children), somnolence, dizziness, headache, pharyngitis, GI disorders, fatigue.
Full prescribing information and references available from Clonmel Healthcare Ltd. Telephone: (052) 6177777. Fax: (052) 6177791. E-mail: medicalinformation@clonmel-health.ie